Details of the Drug
General Information of Drug (ID: DMN4RV0)
Drug Name |
PRX-00023
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Naluzotan; 740873-06-7; PRX-00023; UNII-LQ54E5B4EW; LQ54E5B4EW; CHEMBL209821; Naluzotan [USAN:INN]; PRX 00023; Naluzotan (USAN/INN); SCHEMBL678016; ZINC3963096; BCP20177; BDBM50187377; CS-6740; SB16847; N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide; HY-14848; AN-27536; D09358; L001689; 833C676; Acetamide, N-(3-(4-(4-(((cyclohexylmethyl)sulfonyl)amino)butyl)-1-piperazinyl)phenyl)-; N-(3-[4-(4-Cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 450.6 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 10 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Mood disorder | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 6A60-6E23 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References